SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (12159)2/10/2019 2:33:50 PM
From: scaram(o)uche   of 12215
 
>> are you suggesting <<

No.

First, as you know, metastases don't have the same mutational profile as primaries. Second, antigen-negative cancers arise under pressure of T cell recognition. Third, p53 is just a given, highly-mutated "antigen" for TIL exploration. Doesn't necessarily follow that its peptides represent strong antigens.

But I would suggest that another two decades of such gut-wrenching research will uncover the best of patient-specific antigens/screening assays to use for "whatever car-T looks like in year 2040".... with simultaneous or sequential attack against multiple antigens.

Can't begin to imagine how many hours Dr. Malekzadeh has devoted to this research.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News